Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
13 December 2018 - 11:00PM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment
of Peter S. Greenleaf to the Company’s Board of Directors.
Mr. Greenleaf has over 20 years of biopharmaceutical experience,
and currently serves as the Chief Executive Officer of Cerecor Inc.
(NASDAQ: CERC), a biopharmaceutical company focused on neurological
and pediatric disorders. He is also Chairman of the Board at
BioDelivery Sciences (NASDAQ: BDSI), a specialty pharmaceutical
company focused on pain management and addiction medicine.
Leonard S. Jacob, M.D., Ph.D., Chairman of the
Board of Antares Pharma, stated, “We are pleased to announce the
addition of a seasoned pharmaceutical executive to the Antares
Board of Directors. Peter Greenleaf joins Antares at an
important time in our Company’s history. We believe his
experience in commercial operations and strategy functions will
serve to compliment the Antares team as we prepare to launch
XYOSTED and any potential future products. We look forward to
Peter’s contributions.”
“I am pleased to be joining Antares Pharma
during this exciting period of time for the Company,” said Peter S.
Greenleaf. “Three new drug device combination product
approvals in 2018 could significantly impact revenue growth in 2019
and beyond, resulting in a positive effect on value creation for
our shareholders. I look forward to sharing my expertise and
industry experience as we work to expand our existing
business.”
Previously, Mr. Greenleaf served as Chairman and
CEO of Sucampo Pharmaceuticals and led the Company’s acquisition by
Mallincrodt Pharmaceuticals for $1.2 billion. Prior to
joining Sucampo Pharmaceuticals, Mr. Greenleaf held senior
positions spanning commercial, corporate development and strategy
functions at several pharmaceutical companies. Notably, he
served as President of Medimmune LLC, the biologics arm of
AstraZeneca, and President of Medimmune Ventures, a wholly owned
venture capital fund within the AstraZeneca Group. Mr.
Greenleaf is currently a member of the Board of Directors of
Eyetech Pharmaceuticals and was previously a member of the Board of
Directors of the Biotechnology Industry Organization (BIO) serving
on the Governing Boards of the Emerging Companies and Health
Sectors. He earned his M.B.A. from St. Joseph’s University
and a B.S. from Western Connecticut University.
About Antares Pharma
Antares Pharma, Inc. is a specialty
pharmaceutical company focused on the development and
commercialization of self-administered parenteral pharmaceutical
products using advanced drug delivery auto injector
technology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
advanced stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals,
Inc. and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary
products include XYOSTED™ (testosterone enanthate) injection,
OTREXUP® (methotrexate) injection for subcutaneous use and
Sumatriptan Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the contributions of
Peter S. Greenleaf and increased shareholder value; market
acceptance, adequate reimbursement coverage and commercial success
of XYOSTED™ and future revenue from the same; market acceptance of
Teva’s generic epinephrine auto-injector product and future revenue
from the same; successful completion of the transaction with
Ferring International Center, S.A.; future market acceptance and
revenue from Makena® subcutaneous auto injector; Teva’s ability to
successfully commercialize VIBEX® Sumatriptan Injection USP and the
amount of revenue from the same; continued growth of prescriptions
and sales of OTREXUP®; the timing and results of the
Company’s or its partners’ research projects or clinical trials of
product candidates in development including projects with Teva and
Pfizer; actions by the FDA or other regulatory agencies with
respect to the Company’s products or product candidates of its
partners; continued growth in product, development, licensing and
royalty revenue; the Company’s ability to obtain financial and
other resources for its research, development, clinical, and
commercial activities and other statements regarding matters that
are not historical facts, and involve predictions. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance, achievements or
prospects to be materially different from any future results,
performance, achievements or prospects expressed in or implied by
such forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:Jack HowarthVice
President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Apr 2024 to May 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From May 2023 to May 2024